Zobrazeno 1 - 8
of 8
pro vyhledávání: '"August F. Zabernigg"'
Autor:
Gabriel Rinnerthaler, Simon P. Gampenrieder, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Margit Sandholzer, August F. Zabernigg, Daniel Egle, Christopher Hager, Petra Pichler, Florian Roitner, Johannes Andel, Kathrin Strasser-Weippl, Michael Knauer, Michael Hubalek, Christian F. Singer, Richard Greil
Publikováno v:
Cancer Research. 83:P3-05
Background: Hormone-receptor (HR) status, HER2 Status, de novo metastatic disease, distant recurrence-free interval (DRFI), and visceral disease are known prognostic factors in metastatic breast cancer (MBC). Therefore, in the majority of clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0e32f9a0b2d18076dbbc62f6d3aed29
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-49
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-49
Autor:
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marij Balic, Sonja Heibl, August F Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christopher Hager, Michael Knauer, Michael Hubalek, Christian F Singer, Richard Greil
Publikováno v:
Cancer Research. 82:P1-21
Background: BM are generally associated with poor prognosis and with neurological impairments making BM a major limitation of life expectancy and quality of life in MBC. Real-world data are needed in order to quantify and better characterize this spe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14f8681a4166c26a9774b3cbe1cec808
https://doi.org/10.1158/1538-7445.sabcs21-p1-21-08
https://doi.org/10.1158/1538-7445.sabcs21-p1-21-08
Autor:
Gabriel Rinnerthaler, Simon P Gampenrieder, Christoph Tinchon, Andreas Petzer Petzer, Marija Balic, Heibl Sonja, August F Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christophe Hager, Michael Hubalek, Michael Knauer, Christian F Singer, Richard Greil
Publikováno v:
Cancer Research. 82:P1-16
Background: Despite the advances by targeted therapies, particularly in HER2-positive and hormone receptor (HR)-positive metastatic breast cancer (MBC), chemotherapy remains a mainstay of the treatment in all breast cancer subtypes. Response probabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4aa41106f53bd0c171b3d45688056552
https://doi.org/10.1158/1538-7445.sabcs21-p1-16-03
https://doi.org/10.1158/1538-7445.sabcs21-p1-16-03
Autor:
Simon P. Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Margit Sandholzer, August F. Zabernigg, Daniel Egle, Christopher Hager, Petra Pichler, Florian Roitner, Johannes Andel, Kathrin Strasser-Weippl, Michael Knauer, Michael Hubalek, Christian F. Singer, Richard Greil
Publikováno v:
Cancer Research. 83:P4-01
Background: New anti-HER2 drugs such as tucatinib and trastuzumab deruxtecan (T-DXd) have shown to improve survival of HER2+ MBC in clinical phase III trials. To allow a future confirmation of this survival advantage in real world, we evaluated the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70a4b8526bec048e7dcf2bc9c4a9d0b4
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-27
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-27
Publikováno v:
Leukemia & Lymphoma. 2023 Supplement, Vol. 94, ps1-S197. 197p.
Autor:
Margit Sandholzer, August Zabernigg, Florian Roitner, Daniel Egle, Michael Knauer, Richard Greil, Sonja Heibl, Christoph Tinchon, Daniela Voskova, Michael Hubalek, Gabriel Rinnerthaler, Andreas L. Petzer, Christoph Suppan, Johannes Andel, Simon Peter Gampenrieder, Christian F. Singer
Publikováno v:
Cancer Research. 81:PS12-21
Background: International guidelines recommend endocrine-based first-line therapy [ET] in hormone receptor-positive, HER2-negative (HR+/HER2- or luminal) metastatic breast cancer (MBC), nowadays in combination with a CDK4/6 inhibitor. Several real-wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a76308387e2dd357e188a5db501d998e
https://doi.org/10.1158/1538-7445.sabcs20-ps12-21
https://doi.org/10.1158/1538-7445.sabcs20-ps12-21
Autor:
Michael Knauer, Gabriel Rinnerthaler, Sonja Heibl, Simon P. Gampenrieder, Richard Greil, Johannes Andel, August Zabernigg, Andreas L. Petzer, Christoph Suppan, Margit Sandholzer, Christian F. Singer, Daniel Egle, Daniela Voskova, Christoph Tinchon, Florian Roitner, Michael Hubalek
Publikováno v:
Cancer Research. 81:PS1-41
Background: Metastatic breast cancer (MBC) is generally thought to be a systemic and incurable disease requiring systemic therapy. However, surgical resection of oligometastatic disease might be of benefit similar to other malignant diseases. Here, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::911e483d132a7adf07af456c23266fc7
https://doi.org/10.1158/1538-7445.sabcs20-ps1-41
https://doi.org/10.1158/1538-7445.sabcs20-ps1-41
Autor:
Michael Hubalek, Marija Balic, Johannes Andel, Christoph Tinchon, Holger Rumpold, David Fuchs, Simon Peter Gampenrieder, Christian F. Singer, Michael Knauer, Andreas L. Petzer, Sonja Heibl, Gabriel Rinnerthaler, Richard Greil, August Zabernigg, Daniel Egle
Publikováno v:
Cancer Research. 80:P5-06
Background: Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with poor prognosis. In recent years, major progress has been made in the treatment of metastatic breast cancer (MBC), especia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c8eae42fc62d5e1565c484c42faa8db
https://doi.org/10.1158/1538-7445.sabcs19-p5-06-29
https://doi.org/10.1158/1538-7445.sabcs19-p5-06-29